Researchers have reported a signicant and positive relationship between the amount of virus present in a throat swab sample and the severity of COVID-19 disease.
Researchers have reported a signicant and positive relationship between the amount of virus present in a throat swab sample and the severity of COVID-19 disease.
The higher the relative viral load in the sample, the greater the organ damage, and the longer it would take for the viral RNA count to turn negative, according to results published in Viral Immunology, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.
In "Correlation Between Relative Nasopharyngeal Virus RNA Load and Lymphocyte Count Disease Severity in Patients with COVID-19," Wei Zhang and coauthors from The First Aliated Hospital of Nanchang University in Jiangxi, China collected nasopharyngeal samples from patients with mild and severe COVID-19.
Related: Cotiviti Launches COVID-19 Outbreak Tracker to Forecast Potential “Hot Spots” in US
The researchers measured the level of viral RNA in the sample, also known as the viral load. Viral load correlated positively with the severity of disease symptoms and with increased inammatory factors. There was a negative correlation between SARS-CoV-2 viral load and lymphocytes, such as CD4+ and CD8+T lymphocytes, which fight infection, the report says.
David L. Woodland, PhD, editor-in chief of Viral Immunology and Adjunct Member of the Trudeau Institute in Saranac Lake, NY, states they currently have only a limited understanding of why some patients with the SARS- CoV-2 virus develop severe, life-threatening symptoms, whereas others do not.
In the report, Zhang and colleagues present data correlating viral loads in the nasopharynx with disease severity and progression. These important findings potentially offer medical professionals with crucial information when deciding on treatment options for COVID-19 patients.
This week on Tuning Into The C-Suite Briana Contreras spoke with Dr. Scott Hayworth, president and CEO of New York-based CareMount Medical. In this interview, the two discussed the importance of patients staying in contact with their doctors for the sake of reducing public health risks and to discuss ongoing care options with them.
Listen
Eric Levin talks PBMs and how Scripta is Tackling the Market's Challenges for Patients
July 22nd 2020MHE's Briana Contreras spoke with CEO of Scripta, Eric Levin. The two discussed the current state of the pharmacy benefit market and how the Scripta organization has been assisting its clients and their prescriptions prior to the COVID-19 pandemic and during.
Listen